Skip to main content

Table 1 Demographic characteristics of patients with combined hepatocellular carcinoma and cholangiocarcinoma, hepatocellular carcinoma, and cholangiocarcinoma

From: Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis

Characteristics

Total (n = 505)

cHCC-CC (n = 35)

HCC (n = 419)

CC (n = 51)

p value

Male

404 (80.0)

28 (80.0)

343 (81.9)b

33 (64.7)

0.015

Age (years)

61 (32–87)

57 (37–79)a

62 (32–87)

60 (33–85)

0.211

Hypertension

208 (41.2)

16 (45.7)

178 (42.5)b

14 (27.5)

0.102

Diabetes Mellitus

119 (23.60

3 (8.6)a

102 (24.3)

14 (27.5)c

0.085

Smoking

208 (48.6)

27 (47.4)

87 (20.8)

8 (15.7)

0.695

Alcohol use

102 (20.2)

7 (20.0)

74 (17.7)

4 (7.8)c

0.043

HBV positive

227 (45.0)

15 (42.9)

186 (44.4)

26 (51.0)

0.649

HCV positive

124 (24.6)

8 (22.9)

98 (23.9)

18 (35.3)

0.171

Total Bilirubin

0.95 ± 0.42

0.93 ± 0.32

0.95 ± 0.42

0.94 ± 0.46

0.982

Albumin

4.1 ± 0.3

4.0 ± 0.3

4.1 ± 0.3

4.2 ± 0.2

0.308

INR

1.04 ± 0.07

1.03 ± 0.04

1.04 ± 0.07

1.05 ± 0.12

0.451

Cirrhosis

163 (32.3)

12 (34.4)

145 (34.6)b

6 (11.8)c

0.004

Child–Pugh class A

489 (96.8)

35 (100)

403 (96.5)

51 (100)

0.399

Edmondson–Steiner Grades, I–II

322 (63.7)

18 (51.4)

292 (69.6)b

12 (23.5)

0.404

Tumor size

5.3 ± 3.3

5.8 ± 2.1

5.2 ± 3.4

5.3 ± 2.4

0.623

Tumor size ≥ 5 cm

225 (45.2)

24 (68.6)a

178 (42.5)b

23 (52.3)

0.007

Tumor number (≥ 2)

51 (10.2)

3 (8.6)

46 (11.0)

2 (4.5)

0.385

AFP (ng/mL) ≥ 200

91(21.3)

8 (22.9)

115 (27.4)b

3 (5.9)c

0.003

ICG%

11.1 ± 7.9

10.7 ± 5.5

11.3 ± 8.3

9.6 ± 5.5

0.359

Operative margin > 1 cm

361 (71.4)

25 (71.4)

306 (73.0)b

30 (58.8)c

0.003

Major hepatectomy

257 (50.8)

19 (54.2)

203 (48.4)b

35 (68.6)c

0.007

Microvascular invasion

152 (30.1)

13 (37.1)

131 (31.3)b

8 (15.7)c

0.047

Macrovascular invasion

72 (14.3)

5 (14.3)

66 (15.8)b

1 (2.0)c

0.029

Lympho nodules metastasis

20 (4.0)

7 (20.2)a

5 (1.2)b

8 (15.7)

< 0.0001

Distal metastasis

10 (2.0)

0 (0)

7 (1.7)b

3 (5.9)

0.086

AJCC stage, I–II

383 (75.8)

27 (77.1)

320 (76.3)b

36 (70.5)

< 0.0001

Antiviral therapy

282 (55.8)

18 (51.4)

239 (57.0)

25 (49.0)

0.168

Recurrence

135 (26.7)

9 (25.7)

120 (28.6)b

6 (11.8)

0.036

Recurrence per 100 person-years

33.7

42.1

38.5b

25.3

< 0.0001

Mortality

149 (29.5)

14 (40.0)a

108 (25.8)b

27 (52.8)

< 0.0001

Mortality per 100 person-years

94.1

104.1a

86.7b

113.8

< 0.0001

Follow-up times (months)

38 (1–94)

31 (4–75)a

40 (1–94)b

26 (1–85)

< 0.0001

  1. Data are presented as the median (range) or number (percentage).
  2. HBV Hepatitis B virus, HCV Hepatitis C virus, INR international normalized ratio, AFP alpha-fetoprotein, ICG indocyanine green, AJCC American Joint Committee on Cancer
  3. ap < 0.05, cHCC-CC versus HCC
  4. bp < 0.05, cHCC-CC versus CC
  5. cp < 0.05, HCC versus CC